Holen Sie sich die Stockscreener-App
15.02
0.07%
0.025
Schlusskurs vom Vortag:
$14.99
Offen:
$15.12
24-Stunden-Volumen:
897.42K
Relative Volume:
0.35
Marktkapitalisierung:
$3.57B
Einnahmen:
$510.17M
Nettoeinkommen (Verlust:
$146.93M
KGV:
25.07
EPS:
0.599
Netto-Cashflow:
$27.51M
1W Leistung:
-2.53%
1M Leistung:
-6.77%
6M Leistung:
-6.89%
1J Leistung:
-16.25%
1-Tages-Spanne:
$14.86
$15.22
1-Wochen-Bereich:
$14.86
$16.18
52-Wochen-Spanne:
$13.76
$25.67
Adma Biologics Inc Stock (ADMA) Company Profile
Firmenname
Adma Biologics Inc
Sektor
Branche
Telefon
(201) 478-5552
Adresse
C/O ADMA BIOLOGICS, INC., RAMSEY
Compare ADMA vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADMA
Adma Biologics Inc
|
15.00 | 3.57B | 510.17M | 146.93M | 27.51M | 0.599 |
|
VRTX
Vertex Pharmaceuticals Inc
|
471.80 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
746.16 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
696.52 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.65 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.37 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Adma Biologics Inc Stock (ADMA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-07-19 | Fortgesetzt | Raymond James | Strong Buy |
| 2022-10-13 | Eingeleitet | Mizuho | Buy |
| 2021-11-11 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2021-11-09 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2019-06-04 | Eingeleitet | Jefferies | Buy |
| 2019-04-15 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-07 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-12-11 | Bestätigt | Maxim Group | Buy |
| 2017-11-14 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2017-01-23 | Hochstufung | Maxim Group | Hold → Buy |
| 2016-08-01 | Herabstufung | Maxim Group | Buy → Hold |
| 2016-07-25 | Bestätigt | Maxim Group | Buy |
| 2015-05-13 | Bestätigt | Maxim Group | Buy |
| 2014-12-08 | Eingeleitet | Oppenheimer | Outperform |
| 2014-12-01 | Bestätigt | Maxim Group | Buy |
Alle ansehen
Adma Biologics Inc Aktie (ADMA) Neueste Nachrichten
Adma Biologics (ADMA) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Best Momentum Stocks to Buy for March 12th - Yahoo Finance Singapore
New Strong Buy Stocks for March 12th - Yahoo Finance Singapore
Price-Driven Insight from (ADMA) for Rule-Based Strategy - Stock Traders Daily
Insider Selling: ADMA Biologics (NASDAQ:ADMA) COO Sells $157,800.48 in Stock - MarketBeat
ADMA Biologics (NASDAQ:ADMA) Director Buys $109,690.00 in Stock - MarketBeat
New ADMA Biologics CFO Puts Focus On Margins And Capital Allocation - Yahoo Finance
Returns Recap: Is ADMA Biologics Inc subject to activist investor interestTrade Analysis Report & AI Driven Price Predictions - baoquankhu1.vn
Segall Bryant & Hamill LLC Reduces Stock Position in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Buyback Plan Tests Earnings Story And Valuation Gap - simplywall.st
Legato Capital Management LLC Has $433,000 Holdings in ADMA Biologics Inc $ADMA - MarketBeat
American Century Companies Inc. Purchases 84,934 Shares of ADMA Biologics Inc $ADMA - MarketBeat
Is ADMA Biologics (ADMA) Attractive After Recent Share Price Swings And DCF Upside? - simplywall.st
ADMA Biologics (NASDAQ:ADMA) Upgraded at Zacks Research - MarketBeat
ADMA Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ADMA Biologics (ADMA) Q4 2025 Earnings Transcript - AOL.com
Adma Biologics (ADMA) Upgraded to Strong Buy: Here's Why - Yahoo Finance
Wall Street Analysts Think Adma Biologics (ADMA) Is a Good Investment: Is It? - Finviz
Royce & Associates LP Acquires 292,819 Shares of ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics Inc $ADMA Shares Bought by Rafferty Asset Management LLC - MarketBeat
ADMA Biologics (ADMA) CEO withholds 54,858 shares to cover RSU tax obligations - Stock Titan
ADMA Biologics (ADMA) Announces $200M Capital Return Plan for 20 - GuruFocus
ADMA Biologics Announces $200 Mln Capital Return Plan - Nasdaq
ADMA Biologics Launches Major 2026 Capital Return Plan - TipRanks
ADMA Biologics (NASDAQ: ADMA) recently announced a $125 million accelerated share repurchase agreement with JPMorgan. - Bitget
ADMA Biologics launches $125M accelerated share repurchase as part of ~$200M 2026 buyback plan - TradingView
ADMA Biologics (ADMA) launches $125M accelerated buyback in $200M 2026 plan - Stock Titan
ADMA Biologics commits $125M into rapid buyback, targets $200M in 2026 - Stock Titan
(ADMA) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
ADMA Biologics (ADMA) Valuation After Revenue Growth Guidance Reaffirmation And CFO Transition - simplywall.st
ADMA Biologics (ADMA) Margin Compression Challenges Bullish Growth Narratives Heading Into Earnings - Sahm
Vanguard Group Inc. Sells 388,719 Shares of ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics (NASDAQ:ADMA) Upgraded at Wall Street Zen - MarketBeat
ADMA Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
ADMA Biologics (NASDAQ: ADMA) CFO details stock and option holdings - Stock Titan
A Look At ADMA Biologics (ADMA) Valuation After Record Results Guidance And CFO Appointment - Yahoo Finance
ADMA Q4 EPS Up 14% Y/Y, Revenues Gain From Strong Asceniv Performance - Finviz
ADMA Biologics Inc earnings beat by $0.01, revenue fell short of estimates - Investing.com Nigeria
Westfield Capital Management Co. LP Takes $74.87 Million Position in ADMA Biologics Inc $ADMA - MarketBeat
ADMA Biologics CFO Shift Puts Spotlight On Margins And Valuation - simplywall.st
New ADMA Biologics CFO Takes Helm As Valuation Gap Draws Focus - Yahoo Finance
Decoding ADMA Biologics Inc (ADMA): A Strategic SWOT Insight - GuruFocus
ADMA Biologics Inc (ADMA) Q4 2025 Earnings Call Highlights: Stro - GuruFocus
ADMA Biologics (ADMA) Reports Strong 2025 Results and Positive O - GuruFocus
ADMA Biologics Reports Strong Q4 2025 Earnings and Positive Outlook - Intellectia AI
ADMA Biologics Q4 2025 Earnings Call Transcript - MarketBeat
ADMA forecasts $635M revenue for 2026 as ASCENIV drives margin expansion and new supply deals extend growth runway - MSN
ADMA Biologics Q4 Earnings Call Highlights - MarketBeat
ADMA Biologics Inc reports results for the quarter ended September 30Earnings Summary - TradingView
ADMA Biologics Says Brad Tade Is Retiring As Chief Financial Officer - TradingView
Earnings call transcript: ADMA Biologics reports strong Q4 2025 growth - Investing.com
Finanzdaten der Adma Biologics Inc-Aktie (ADMA)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):